ArticleBritish journal of clinical pharmacology2021
Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.
Article in British journal of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 7 citations in OpenAlex.
- Application of SHAP values for inferring the optimal functional form of covariates in pharmacokinetic modeling.CPT: pharmacometrics & systems pharmacology · 2022Article
- Evidence-Based Minireview: For overweight or obese persons with hemophilia A, should factor VIII dosing be based on ideal or actual body weight?Hematology. American Society of Hematology. Education Program · 2021Review
- Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.Blood advances · 2021Review
- Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients.British journal of clinical pharmacology · 2021Article
- Impact of extreme weight loss on factor VIII concentrate pharmacokinetics in haemophilia.BMJ case reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsUnder- and, especially, overdosing of replacement therapy in haemophilia A patients may be prevented by application of other morphometric variables than body weight (BW) to dose factor VIII (FVIII) concentrates. Therefore, we aimed to investigate which morphometric variables best describe interindividual variability (IIV) of FVIII concentrate pharmacokinetic (PK) parameters.
methodsPK profiling was performed by measuring 3 FVIII levels after a standardized dose of 50 IU kg
resultsIn total, 57 haemophilia A patients (FVIII≤0.05 IU mL
conclusionIBW is the most suitable morphometric variable to explain interindividual FVIII PK variability and is more appropriate to dose overweight and obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.